Tranexamic Acid Tablet
Product Images NDC 59651-839

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Tranexamic Acid (NDC 59651-839). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tranexamic Fig1)

Mean Menstrual Blood Loss (mL): - Baseline: First Cycle, Second Cycle, Third Cycle, Fourth Cycle, Fifth Cycle, Sixth Cycle The data provided appears to be related to a study on menstrual blood loss and the effects of Tranexamic Acid compared to a placebo. The text includes measurements of blood loss in milliliters (mL) for different treatment periods. It also mentions a 3-cycle and a 6-cycle study. The text provides information about the dosage of Tranexamic Acid (3900 mg/day) and the inclusion of a placebo group.*

FDA Label Image

Package Label-principal Display Panel (650 mg (30 Tablets Bottle))

FDA Label Image

Chemical Structure (Tranexamic Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.